The Absolute Effect / Oncology Evidence
Bladder Cancer Trial Evidence
Bladder cancer evidence organized by treatment setting, including neoadjuvant chemotherapy, bladder-preserving chemoradiotherapy, adjuvant systemic treatment and advanced disease.
Featured evidence
- SWOG 8710 — neoadjuvant cisplatin-based chemotherapy before cystectomy.
- VESPER — dose-dense MVAC versus gemcitabine-cisplatin before cystectomy.
- BC2001 — concurrent chemotherapy with radiotherapy for bladder preservation.
- CheckMate 274 — adjuvant nivolumab after radical surgery in high-risk urothelial carcinoma.
- IMvigor010 — adjuvant atezolizumab after surgery.
- EORTC 30994 — immediate versus deferred chemotherapy after radical cystectomy.